
Eggshell membrane for knee osteoarthritis: small effects and product-specific evidence
A 2024 meta-analysis found small average improvements from eggshell membrane, while individual trials and allergy questions limit broad claims.
Eggshell-membrane supplements show small short-term signals, but the evidence is product-specific and does not demonstrate cartilage rebuilding.
The ingredient story sounds more direct than the biology
Eggshell membrane contains proteins and glycosaminoglycans associated with connective tissue. Marketing can turn that composition into a simple rebuilding story: consume joint materials and the body will place them into damaged cartilage. Digestion and metabolism make that inference unreliable. Human trials must test whether the oral product changes pain or function.
Natural eggshell membrane products also vary in processing and characterization. The evidence for one branded 500-milligram preparation does not automatically support every capsule made from eggs. Finished-product matching matters as much as the front-label ingredient name.

The early randomized trial had mixed endpoints
A multicenter double-blind trial randomized 67 people with knee osteoarthritis to eggshell membrane or placebo for eight weeks. Some pain and stiffness response measures favored the supplement as early as ten days. Overall WOMAC and function scores did not improve significantly, although trends were reported.
Selective emphasis can make this result look more uniform than it was. Pain, stiffness, function and total scores are related but distinct. The conclusion should name which outcomes separated from placebo, how large the differences were and which primary measures remained uncertain.
The 2024 meta-analysis found small pooled effects
A systematic review searched through July 2024 and identified seven randomized trials, with five included in meta-analysis. Eggshell membrane produced a small improvement in total WOMAC and pain scores. The authors called the ingredient promising while also requesting larger, high-quality trials and longer follow-up.
A statistically significant standardized mean difference does not tell a shopper how many points a particular product will change on a familiar scale. Small pooled effects may not reach a meaningful threshold for every person. Study sponsorship, risk of bias, product similarity and missing data remain important when judging the average.
Egg allergy and blends require attention
Because the material comes from eggs, people with egg allergy should not assume it is safe without professional guidance. Manufacturing may affect residual proteins, but a label cannot replace an individualized allergy assessment. Digestive effects, other health conditions and medicine use should also be considered.
Many joint formulas combine eggshell membrane with collagen, turmeric or minerals. A blend trial cannot identify the independent contribution of each ingredient unless the comparison is designed for that purpose. Likewise, a study of membrane alone does not prove that a lower amount inside a complex formula produces the same result.

Keep the claim at the symptom level
The trials evaluated short-term symptoms and function; they did not show cartilage regeneration or disease modification. Connective-tissue imagery and composition should not be used to imply structural repair. That stronger promise requires appropriate imaging, long follow-up and reproducible controlled findings.
A practical decision should compare the exact product with the studied preparation, define a meaningful goal and set a review date. Small evidence signals may justify further research or a supervised trial in an appropriate person, but they do not justify replacing diagnosis, exercise or established care with a shell-derived supplement.
Small pooled effects need a real-world translation
Future reviews should translate standardized effects into familiar scales and compare them with a prespecified threshold for meaningful improvement. They should also test whether the estimate changes when industry-linked, high-risk-of-bias or very short trials are removed. Without those analyses, statistical significance can sound larger and more dependable than the experience likely to be for an individual user.
Longer trials could determine whether an early pain response persists and whether stopping the product changes symptoms. They should not imply structural protection unless cartilage or progression is measured appropriately. Clear reporting of egg allergy screening, manufacturing controls and adverse events would also make the safety conclusion more useful than the broad statement that a natural product was well tolerated. Studies should report absolute changes, responder thresholds and missing data. Independent trials would reduce uncertainty about whether results travel beyond one branded formulation. Consumer decisions need that clarity.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.